MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) shares were up 2.2% on Tuesday . The stock traded as high as $7.42 and last traded at $7.40. Approximately 10,909 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 99,399 shares. The stock had previously closed at $7.24.
Analyst Ratings Changes
Several equities research analysts have weighed in on MLTX shares. SVB Leerink started coverage on shares of MoonLake Immunotherapeutics in a research report on Thursday, August 25th. They issued an “outperform” rating and a $17.00 price objective for the company. HC Wainwright started coverage on shares of MoonLake Immunotherapeutics in a research note on Thursday, July 21st. They issued a “buy” rating and a $28.00 target price on the stock. Cowen started coverage on shares of MoonLake Immunotherapeutics in a research note on Thursday, July 7th. They issued an “outperform” rating on the stock. Finally, Cowen started coverage on shares of MoonLake Immunotherapeutics in a research note on Thursday, July 7th. They set an “outperform” rating on the stock.
MoonLake Immunotherapeutics Trading Up 2.2 %
The business has a fifty day simple moving average of $7.17.
Hedge Funds Weigh In On MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Company Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
- Get a free copy of the StockNews.com research report on MoonLake Immunotherapeutics (MLTX)
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.